Diagnostic performance of tumor markers AFP and PIVKA-II in Chinese hepatocellular carcinoma patients

• Published in: Tumor biology Vol. 39; no. 6; p. 1010428317705763
• Main Authors: Huang, Shujing, Jiang, Feifei, Wang, Ying, Yu, Yanhua, Ren, Siqian, Wang, Xiaowei, Yin, Peng, Lou, Jinli
• Format: Journal Article
• Language: English
• Published: London, England SAGE Publications 01.06.2017; Sage Publications Ltd; IOS Press
• Subjects: Adult; Age; Aged; alpha-Fetoproteins - metabolism; Authorship; Biomarkers; Biomarkers - blood; Biomarkers, Tumor - blood; Carcinoma, Hepatocellular - blood; Carcinoma, Hepatocellular - pathology; Carcinoma, Hepatocellular - virology; China; Diagnosis; Enzyme immunoassay; Female; Hepatitis; Hepatitis B; Hepatitis B - blood; Hepatitis B - pathology; Hepatitis B - virology; Hepatitis B virus - pathogenicity; Hepatocellular carcinoma; Humans; Immunoassay; Infections; Liver cancer; Liver Cirrhosis - blood; Liver Cirrhosis - pathology; Liver diseases; Liver Neoplasms - blood; Liver Neoplasms - pathology; Liver Neoplasms - virology; Male; Medical diagnosis; Metastasis; Middle Aged; Mortality; Protein Precursors - blood; Prothrombin; Tumor markers; Variance analysis; Vitamin K; α-Fetoprotein; United States > US; China; Diagnosis; alpha-fetoprotein; hepatocellular carcinoma; protein induced by vitamin K antagonist-II
• ISSN: 1010-4283; 1423-0380
• DOI: 10.1177/1010428317705763

Alpha-fetoprotein is an effective biomarker as an aid in hepatocellular carcinoma detection in many countries. However, alpha-fetoprotein has its limitations, especially in early hepatocellular carcinoma diagnosis. Protein induced by vitamin K absence or antagonist-II is another biomarker that is used for hepatocellular carcinoma detection. The aim of this study is to compare the diagnostic performance of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II alone and in combination to explore improving biomarker performance as an aid in early hepatocellular carcinoma detection. In this study a total of 582 serum samples including 132 hepatocellular carcinoma patients, 250 non-hepatocellular carcinoma patients, and 200 healthy volunteers were collected. Alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II levels were measured by both chemiluminescent enzyme immunoassay on LUMIPULSE platform and by chemiluminescent microparticle immunoassay on ARCHITECT platform. Receiver operation characteristic curve analyses were performed for each biomarker and in combination. The results showed that Alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in combination have shown higher area under the curve compared to alpha-fetoprotein alone for diagnosis in whole patients (0.906 vs 0.870) in hepatocellular carcinoma early-stage patients (0.809 vs 0.77) and in hepatitis B virus–related hepatocellular carcinoma patients (0.851 vs 0.788) with ARCHITECT platform. Protein induced by vitamin K absence or antagonist-II showed higher area under the curve than alpha-fetoprotein for diagnosis of hepatitis B virus–related hepatocellular carcinoma patients (0.901 vs 0.788).We conclude that Combining alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II may improve the diagnostic value for early detection of hepatocellular carcinoma. Protein induced by vitamin K absence or antagonist-II performs better than alpha-fetoprotein in diagnosis of hepatitis B virus–related hepatocellular carcinoma patients.